chronic gout
Other · 2014–2017
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| febuxostat Treatment of chronic gout in patients with contraindication to, or intolerance of, allopurinol. | Jul 2017 | Not recommended | none received |
| febuxostat Chronic gouty arthritis associated with hyperuricaemia in adults with gout, specifically for patients intolerant to allopurinol. | Mar 2014 | Not recommended | no section in document |
What the PBS pays
$3M in government benefit over 2024–25, across 78,347 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| febuxostat | $3.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.